The pharmacokinetic properties of carumonam-(AMA-1080, Ro 17-2301) were studied in mice, rats, rabbits, dogs, and cynomolgus monkeys and compared with those of aztreonam. Carumonam administered subcutaneously in mice or intramuscularly in rats, rabbits, dogs, and cynomolgus monkeys at a dose of 20 mg/kg was readily absorbed and distributed at high concentrations in the plasma, kidneys, liver, and lungs, as was aztreonam. The peak level of carumonam in plasma, ranging from 41 ,Lg/ml in mice to 68 ,ig/ml in monkeys; the area under the plasma concentration-time curve; ranging from 20 ,ug * h/ml in mice to 80 ,ug * h/ml in monkeys; the plasma half-life, ranging from 0.24 h in mice to 1.10 h in dogs; and the plasma clearance, ranging from 4.5 ml/min per kg in monkeys to 16.7 ml/min per kg in mice, resembled respective values of aztreonam. In rats, carumonam was eliminated faster than aztreonam. The levels of both antibiotics in the kidneys and liver were usually higher than respective levels in plasma. The level of carumonam in the kidney was usually higher than that of aztreonam, whereas the level of aztreonam in the liver was usually higher than that of carumonam. Both antibiotics showed similar distribution in the lung and spleen; the leveis in these tissues were less than the levels in plasma. Carumonam was excreted mainly in the urine; the recovery ranged from 52% (froln dogs) to 73% (from rabbits). The urinary recovery of carumonam frpom mice, rats, and monkeys was higher, but the recovery of carumonam fromn rabbits and dogs was lower than that of aztreonam. The biliary excretion of carumonam, amounting to 4.1% from rats and less than 0.3% from rabbits and dogs, was smaller than that of aztreonam, amounting to 19.1% from rats and around 1% front rabbits and dogs. The extent of protein binding at 20 ,ig of carumonam per ml was lower than that of aztreonam. For all species except dogs, which have very low binding in their serum (11% for carumonam and 20% tor aztreonam), the binding of carumonam ranged from 21% (in rabbits) to 36% (in rats), whereas that of aztreonam ranged from 55% (in rabbits) to 85% (in rats). Thus, the plasma pharmacokineties of carumonam and aztreonam were generally similar for all animals tested except dogs, but the two antibiotics differed slightly in their distribution in tissue, excretion, and protein binding in serum;
Carumonam (AMA-1080, Ro 17-2301), (3S,4S)-3-[2-(2-aminothiazoly-4-yl)-(Z)-2-carboxymethoxyiminoacetamido]-4-carbamoyloxymethyl-2-azetidinone-1-sulfonic acid (see Fig. 1 ), has potent in vitro and in vivo activities against a wide range of aerobic gram-negative bacteria such as members of the family Enterobacteriaceae, Pseudomonas aeruginosa, and Haemophilus influenzae (4) . Its activity is similar to that of the structurally related antibiotic aztreonam (12) , but it shows stronger activity than aztreonam against Klebsiella oxytoca, Klebsiella pneumoniae, and Enterobacter cloacae (4) . In the studies reported here, the pharmacokinetic properties of carumonam in experimental animals were compared with those of aztreonam ( Fig. 1) (12) .
(These results were presented in part at the 13th International Congress of Chemotherapy, Vienna, Austria, 1983.) MATERIALS AND METHODS Antibiotics. Carumonam and its metabolite, AMA-1294, were prepared in our division, and aztreonam was obtained from Hoffmann-La Roche, Inc., Nutley, N.J.
Animals. Five-week-old male Slc:ICR mice weighing 20 to 25 g, 7-week-old male Jcl:SD rats weighing 210 to 250 g, male New Zealand White rabbits weighing 2.5 to 3.5 kg, male and female beagle dogs weighing 10 to 15 kg, and female * Corresponding author. cynomolgus monkeys weighing 2.8 to 3.7 kg were used. They were deprived of feed for 16 to 18 h before the antibiotic was administered; water was given ad libitum.
Antibiotic administration. Just before use, each antibiotic was dissolved in a solution containing NaHCO3 equimolar to the antibiotic. A single dose of 20 mng of the antibiotic per kg of body weight was administered subcutaneously to mice (2 mg/ml, 0.1 ml/10 g) and intramuscularly to rats (10 mg/ml, 0.2 ml/100 g), rabbits (40 mg/ml, 0.5 ml/kg), dogs (100 mg/ml, 0.2 ml/kg), and monkeys (20 mg/ml per kg).
Specimens for antibiotic bioassay. Blood specimens collected on heparin were obtained from the axillary artery and vein of mice, rats, and rabbits that were anesthetized with ethyl ether and killed at each sampling period. Blood specimens of monkeys were collected successively from the femoral vein of the unanesthetized animals, and those of dogs were collected from the saphena and median veins of the unanesthetized animals. Plasma was separated by centrifugation at 2,000 x g for 10 min at 2°C.
After the animals were killed by bleeding, the lungs, liver, spleen, and kidneys were removed and washed with saline. The tissues were homogenized with the same part (wt/vol) of 0.1 M,phosphate buffer (pH 7.0) and then homogenized again with 4 parts (vol/vol) of methanol. The homogenates were centrifuged (2,000 x g, 10 min), and the supernatant fluids were subjected to bioassay.
Urine specimens were collected from mice, rats, and monkeys in metabolism cages or with a urethral catheter in unanesthetized rabbits and dogs and anesthetized bile ductcannulated rats and dogs. Bile specimens were collected from the common bile duct cannulated with polyethylene tubing in rats, rabbits, and dogs anesthetized with sodium pentobarbital (Nembutal; Abbott Laboratories, North Chicago, Ill.). All specimens were assayed immediately after each experiment or within 2 days after storage at -80°C. The antibiotic was stable under these conditions. Antibiotic assays. (i) Microbiological assay. Antibiotics in plasma, urine, and bile were assayed by the agar well method with Escherichia coli NIHJ as the test in the tissues of rabbits, dogs, and cynomolgus monkeys were examined at 30 min after 20-mg/kg doses of the antibiotics were administered intramuscularly (Table 4) .
When the levels in tissue were compared 15 min after the drug was administered in rodents and 30 min after administration in other animals, the distribution patterns in the lungs and spleen were similar for all animal species tested with either of the antibiotics. The concentrations in the lungs and spleen were usually lower than the concentrations in plasma. The ratio of the concentration of carumonam in the lungs to that in plasma ranged from 0.27 (in monkeys) to 0.45 (in mice); the lung/plasma ratio of aztreonam ranged from 0.20 (in monkeys) to 0.32 (in mice). The ratio of the concentration of carumonam in the spleen to that in the plasma ranged from 0.05 (in monkeys) to 0.2 (in mice), the spleen/plasma ratio of aztreonam ranged from 0.05 (in monkeys) to 0.11 (in dogs). In contrast, the distribution in the kidneys and liver was 
